

Anti-BLyS/APRIL Antibody (Atacicept)

Introduction


Atacicept is a recombinant fusion protein composed of the Fc portion of human IgG1 and the extracellular domain of the TACI receptor. It inhibits the survival and differentiation of B cells by binding to BLyS (B lymphocyte stimulator) and APRIL (proliferation-inducing ligand), thereby being used to treat autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Product parameters

Alternative Names	TACI-Ig, A-623, TACI-Fc 5
Target Accession	-
Target	BLyS/APRIL
CAS number	845264-92-8
Molecular Weight	-
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	1 mg/mL
Buffer System	100 mM Pro 20 mM Arg pH 5.0.
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 Years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APEx BIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

